Lilly's Donanemab Approved by FDA for Treatment of Early Symptomatic AD; Donanemab, now 1 of 2 antiamyloid medications available, is unique based on evidence that it can be used in limited duration treatment, based on removal of plaque.

Media coverage

• Title	Lilly's Donanemab Approved by FDA for Treatment of Early Symptomatic AD; Donanemab, now 1 of 2 antiamyloid medications available, is unique based on evidence that it can be used in limited duration treatment, based on removal of plaque.
  Media name/outlet	Patient Care
  Country/Territory	United States
  Date	2/07/24
  Persons	Howard Fillit